Recursion Pharmaceuticals/$RXRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Ticker
$RXRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
800
ISIN
US75629V1044
Website
RXRX Metrics
BasicAdvanced
$2.1B
-
-$1.82
0.83
-
Price and volume
Market cap
$2.1B
Beta
0.83
52-week high
$12.36
52-week low
$3.79
Average daily volume
26M
Financial strength
Current ratio
4.114
Quick ratio
3.85
Long term debt to equity
7.76
Total debt to equity
9.948
Interest coverage (TTM)
-278.66%
Profitability
EBITDA (TTM)
-525.584
Gross margin (TTM)
-623.19%
Net profit margin (TTM)
-961.32%
Operating margin (TTM)
-960.08%
Effective tax rate (TTM)
0.09%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-38.51%
Return on equity (TTM)
-86.10%
Valuation
Price to revenue (TTM)
26.998
Price to book
2.22
Price to tangible book (TTM)
4.72
Price to free cash flow (TTM)
-4.025
Free cash flow yield (TTM)
-24.85%
Free cash flow per share (TTM)
-126.96%
Growth
Revenue change (TTM)
29.32%
Earnings per share change (TTM)
12.50%
3-year revenue growth (CAGR)
66.52%
3-year earnings per share growth (CAGR)
11.72%
What the Analysts think about RXRX
Analyst ratings (Buy, Hold, Sell) for Recursion Pharmaceuticals stock.
Bulls say / Bears say
Recursion Pharmaceuticals' acquisition of Exscientia for $688 million is expected to enhance its AI-driven drug discovery capabilities and expand its pipeline, positioning the company as a leader in technology-enabled drug development. (reuters.com)
The FDA's initiative to replace animal testing with AI models could increase demand for Recursion's AI-driven drug discovery platform, potentially leading to new partnerships and revenue streams. (finviz.com)
Recursion's Phase 2 trial of REC-994 met its primary safety endpoint and showed encouraging trends in MRI-based efficacy measures, indicating potential for further development in treating symptomatic cerebral cavernous malformation. (finance.yahoo.com)
The resignation of the FDA's chief vaccine regulator has raised concerns about potential delays in drug approvals, which could impact Recursion's pipeline progress. (fool.com)
Director Blake Borgeson's sale of over $78,000 in company stock might signal insider concerns about the company's short-term prospects. (investing.com)
The Bank of New York Mellon Corp reduced its holdings in Recursion by 8.2%, possibly reflecting decreased institutional confidence in the company's future performance. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
RXRX Financial Performance
Revenues and expenses
RXRX Earnings Performance
Company profitability
RXRX News
AllArticlesVideos
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn
Reuters·1 week ago
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
GlobeNewsWire·2 weeks ago
Recursion to Participate in Upcoming Investor Conferences
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Recursion Pharmaceuticals stock?
Recursion Pharmaceuticals (RXRX) has a market cap of $2.1B as of June 20, 2025.
What is the P/E ratio for Recursion Pharmaceuticals stock?
The price to earnings (P/E) ratio for Recursion Pharmaceuticals (RXRX) stock is 0 as of June 20, 2025.
Does Recursion Pharmaceuticals stock pay dividends?
No, Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Recursion Pharmaceuticals dividend payment date?
Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.